Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report

Transplant Proc. 2010 Mar;42(2):601-4. doi: 10.1016/j.transproceed.2010.01.003.

Abstract

Hepatopulmonary syndrome is defined as a triad of liver disease, arterial hypoxemia, and intrapulmonary vascular dilatation. The clinical hallmark of this disorder is the impairment of pulmonary gas exchange, not necessarily correlated with the severity of the underlying liver disease. Liver transplantation (OLT) is the only definitive treatment for this syndrome. However, patients with preoperative partial pressure of arterial oxygen (PaO(2)) under 50 mm Hg are exposed to an unacceptably high postoperative mortality and morbidity. Herein we have described a case of a 15-year-old female patient who underwent OLT and was treated with methylene blue in the early postoperative period to improve hypoxemia. We suggest that the use of methylene blue after liver transplantation can decrease postoperative complications and mortality rates in these patients.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Hepatitis, Autoimmune / surgery*
  • Hepatopulmonary Syndrome
  • Humans
  • Hypoxia / prevention & control*
  • Liver Cirrhosis / etiology
  • Liver Transplantation / physiology*
  • Methylene Blue / therapeutic use*
  • Postoperative Complications / prevention & control

Substances

  • Enzyme Inhibitors
  • Methylene Blue